AstraZeneca Director Pushing to Tie Exec Pay to Big Growth Promises - Pharma News -BoardProspects

AstraZeneca Director Pushing to Tie Exec Pay to Big Growth Promises

Pharma News Mar 2 2015 BoardNews

Soriot and his team fought hard against Pfizer's £55-per-share bid, and in the process promised to send sales soaring to $45 billion by 2023. Last summer, some top shareholders suggested directly linking executive pay to progress toward those goals. And in ...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- Progenics Inked a Merger to Avoid Negotiating a Proxy War. One Activist Still Wants to Fight also published in Pharma News
- Getting Gen-Y on Boards (of Directors) also categorized in BoardNews
- The Other Duty of Corporate Governance also categorized in BoardNews
- Germany's Corporate Governance Problem also categorized in BoardNews
- Netflix: Icahn Says Poison Pill 'Poor Corporate Governance' also categorized in BoardNews
- Corporate Boards: Shifting From Aging Men To New Generation Of Women? also categorized in BoardNews
- Why Should We Care About Corporate Interlocks? also categorized in BoardNews
- Six Years Later, The Problem at HP is Still the Board also categorized in BoardNews
- GlaxoSmithKline CEO Walmsley's Pay Falls to $9.7M as Pandemic Drags on Profits also published in Pharma News
- Taiwan Court Orders Reinstatement Of Two CPDC Board Candidates As Contested Vote Nears also categorized in BoardNews

Search:
Categories
1. BoardProspects Features:
  Board Recruitment Publication, BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
Quotes
1. We're concerned the management get paid out because the share price has gone up, and actually they don't deliver anything to justify these forward-looking revenue targets.
Topics Mentioned
- activist investor
- CEO